ASCO® Data Updates for Dual IO Combination Therapy for the Treatment of Unresectable or Metastatic Melanoma

CCS Banner Series

ASCO® Data Updates for Dual IO Combination Therapy for the Treatment of Unresectable or Metastatic Melanoma

Key updates from ASCO® in the advancements of a DUAL IO therapy for metastatic melanoma and how this treatment option may improve outcomes for patients.

Key Takeaways:

  • Treating patients with unresectable or Metastatic Melanoma with BRAF Status or Wild Type

Time and location

  • Wednesday, July 24, 2024
  • 12:15 PM - 1:00 PM Central Time (CT) Virtual

Faculty

Daniel H. Johnson, MD
  • Daniel H. Johnson, MD
  • Deputy Director of Precision Therapies
  • Program
  • Ochsner, MD Anderson Cancer Center